Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis

Br J Dermatol. 2018 Mar;178(3):798-800. doi: 10.1111/bjd.15504. Epub 2018 Jan 28.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adalimumab / therapeutic use
  • Biomarkers / metabolism
  • Dermatologic Agents / therapeutic use*
  • Epigenesis, Genetic / physiology
  • Etanercept / therapeutic use
  • Female
  • Humans
  • Infliximab / therapeutic use
  • Male
  • Middle Aged
  • Prospective Studies
  • Psoriasis / drug therapy*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Biomarkers
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept